Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids by Lötvall, Jan et al.
RESEARCH Open Access
Comparison of vilanterol, a novel long-acting
beta2 agonist, with placebo and a salmeterol
reference arm in asthma uncontrolled by
inhaled corticosteroids
Jan Lötvall1*, Eric D Bateman2, William W Busse3, Paul M O’Byrne4, Ashley Woodcock5, William T Toler6,
Loretta Jacques7, Caroline Goldfrad8 and Eugene R Bleecker9
Abstract
Background: Current maintenance therapies for asthma require twice-daily dosing. Vilanterol (VI) is a novel long-
acting beta2 agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid
(ICS). Findings from a previous 4-week study suggested that VI has inherent 24-hour activity and is therefore suitable
for once-daily dosing. The study described here was a double-blind, double-dummy, randomised, placebo-controlled
trial, the aim of which was to assess the efficacy of once-daily VI compared with placebo in patients with persistent
asthma. The primary endpoint was change from baseline in 24-hour weighted mean forced expiratory volume in
1 second after 12 weeks of treatment vs. placebo. An active control arm received salmeterol (SAL) twice daily. All
patients were maintained on a stable background dose of ICS.
Results: Patients (n = 347) received VI, placebo or SAL (1:1:1). For the primary endpoint, substantial improvements in
lung function were seen with VI (359 ml), SAL (283 ml) and placebo (289 ml). There were no statistically significant
treatment differences between either the VI (70 ml, P = 0.244) or SAL (−6 ml, P = 0.926) groups and placebo. Both active
treatments were well tolerated, with similarly low rates of treatment-related adverse events compared with placebo.
No treatment-related serious adverse events occurred.
Conclusions: This study failed to show a treatment difference between VI and placebo for the primary endpoint, in
the presence of a placebo response of unforeseen magnitude. Because the placebo response was so large, it is not
possible to draw meaningful conclusions from the data. The reason for this magnitude of effect is unclear but it may
reflect increased compliance with the anti-inflammatory therapy regimen during the treatment period.
Trial registration: NCT01181895 at ClinicalTrials.gov.
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Background
Asthma is a chronic inflammatory disease characterised
by airway hyper-responsiveness which causes narrowing
of airways and obstruction of air flow. This typically oc-
curs following exposure to a stimulus such as an allergen
or chemical and is associated with inflammation of the
airway [1]. This produces symptoms including dyspnoea
(shortness of breath), wheezing and cough that generally
resolve in response to treatment and/or removal of the
triggering stimulus [2]. Exacerbations (‘asthma attacks’)
are worsenings of symptoms associated with acute air-
way inflammation, and are associated with significant
morbidity, mortality and healthcare costs [3].
Spirometry is a fundamental measure in the clinical
management of asthma, characterising lung function
and the presence of airway narrowing by assessing the
degree to which airflow is limited [4]. Specifically, the
forced expiratory volume in one second (FEV1) measure-
ment has been validated for its close correlation with
airway obstruction and is thus predictive for the pres-
ence of asthma and asthma mortality [5].
Asthma treatment is aimed at improving lung function
and symptoms, along with minimising the likelihood of
exacerbations [4]. Short-acting beta2 agonists, which pro-
vide rapid-onset relief of bronchoconstriction, are typically
used on an as-needed basis and are the first line of treat-
ment. For patients with persistent, uncontrolled asthma,
maintenance therapy with inhaled corticosteroids (ICS),
which treat inflammation, and long-acting beta2 agonists
(LABAs), which improve lung function and alleviate
symptoms, are recommended. Current asthma treatment
guidelines [2] recommend the addition of a LABA to ICS
for patients inadequately controlled by ICS monotherapy
and advise against LABA monotherapy.
LABAs currently licensed for asthma, such as salme-
terol (SAL) and formoterol, require twice-daily dosing.
Vilanterol (VI) is chemically distinct from SAL [6] and
has been shown to exhibit faster onset and longer dur-
ation of action in human lung tissue [7]. Clinical studies
have demonstrated 24-hour efficacy of VI in patients
with persistent asthma when administered concurrently
with ICS once daily [8,9]. VI is currently under develop-
ment as a once-daily treatment in combination with flu-
ticasone furoate (FF), a novel ICS shown to be effective
in a range of asthma severities [10-13].
This study sought to evaluate the efficacy and safety of
once-daily VI 25 mcg over 12 weeks in patients with
persistent asthma uncontrolled by ICS alone. This dose
was identified from earlier-phase studies to have the
greatest therapeutic ratio [8]. The main hypothesis for
the study was that VI would exhibit superior efficacy
relative to placebo on the primary endpoint of weighted
mean (0–24 hours) FEV1 after 12 weeks. A SAL refer-
ence arm was also included for benchmarking.
Results
A total of 347 patients at 34 centres in 5 countries were
randomised; 298 completed the study. Patients in all
treatment groups had high mean FEV1 reversibility
(26.2–30.0%, 533.7–650.6 ml) and were symptomatic
during run-in. A summary of patient disposition, includ-
ing withdrawals occurring at screening, prior to random-
isation and during the treatment period, is provided in
Figure 1. Data describing demography (age, sex, duration
of asthma, rescue use at baseline), baseline lung function
(FEV1), reversibility and rescue medication use are pro-
vided in Table 1 and, excepting the latter, are presented
by country (see Additional file 1).
Improvements of >250 ml in the primary endpoint of
weighted mean (0–24 hours) FEV1 were seen after
12 weeks in all treatment groups (Table 2). Neither VI
nor SAL were significantly superior to placebo on the
primary endpoint; a change from baseline of −6 ml com-
pared with placebo was observed in the SAL group. As
the analysis was based on a pre-defined hierarchy
whereby the higher-level endpoint must be significant to
infer significance for endpoints lower in the hierarchy,
no statistical inference can be drawn from the observed
differences for all successive endpoints.
The relative change from baseline in raw data for
weighted mean 0–24 hours serial FEV1 across the three
treatment groups was observed to vary substantially
across the five countries in which study centres were lo-
cated: change from baseline after 12 weeks in the pla-
cebo group ranged from 19 ml (Germany) to 492ml
(Peru) (Table 3), however, there was no evidence of a
treatment interaction by region for the primary endpoint
(p = 0.9178). The outcome of 0–24 hour serial FEV1 as-
sessment is shown in Figure 2.
Percentage of rescue-free 24-hour periods increased
from baseline over the 12 weeks of treatment in all three
treatment groups (VI: 21.7%, SAL: 22.9%, placebo:
14.6%) (Figure 3). Difference from placebo was margin-
ally greater with SAL (8.3% [0.7 – 16.0]) than VI (7.1%
[−0.4 – 14.6]) with some indication of a treatment-by-
region interaction (p = 0.078) although the treatment dif-
ferences between VI and placebo were directionally the
same, favouring VI in all countries but Peru. On symptom-
free 24-hour periods, change from baseline over 12 weeks
relative to placebo was similar for VI (6.7% [−0.5 – 13.8])
or SAL (6.8% [−0.5 – 14.0]) (Figure 4).
Daily trough evening (PM) peak expiratory flow (PEF)
increased from baseline over Weeks 1–12 in all treat-
ment groups. For PM PEF, least squares mean change
from baseline was 24.9 l/min for VI, 18.8 l/min for SAL
and 11.0 l/min for placebo. The differences from placebo
in mean (95% CI) change from baseline were VI: 13.9 l/
min (5.1 – 22.6) and SAL: 7.8 l/min (−1.0 – 16.7). For
morning (AM) PEF (l/min), increases from baseline were
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seen with VI: 28.0, SAL: 23.6 and placebo: 14.2. Differ-
ences from placebo were VI: 13.9 (4.8 – 22.9) and SAL:
9.5 (0.4 – 18.6) (see Additional file 2).
The median (95% CI) time to onset of a ≥12% and
≥200 ml increase from baseline FEV1 on Day 1 was 62 mi-
nutes in the VI group and 122 minutes in the SAL group.
This could not be calculated for the placebo group be-
cause 68% of patients in the placebo group did not achieve
the specified FEV1 increase within 2 hours and were
therefore censored 2 hours post-dose. Hazard ratios for
time (0–2 hours) until patients achieved an increase in
FEV1 of ≥12% and ≥200 ml from baseline vs. placebo for
VI and SAL on Day 1 and Day 84 are shown in Table 4.
A statistical analysis of responders based on the Global
Assessment of Change Questionnaire is presented (see
Additional file 3).
Table 1 Patient demographics and baseline characteristics, ITT population
VI 25 mcg OD (N = 115) SAL 50 mcg BD (N = 116) Placebo (N = 116) Total (N = 347)
Age, years 41.0 (17.81) 41.1 (16.84) 41.7 (16.64) 41.3 (17.06)
Female sex, n (%) 68 (59) 77 (66) 59 (51) 204 (59)
Duration of asthma, years 17.61 (13.54) 19.41 (14.87) 18.43 (13.33) 18.49 (13.91)
Screening pre-bronchodilator FEV1 (ml) 2133 (631.4) 2078 (591.7) 2204 (653.0) 2139 (626.2)
Screening % predicted FEV1 66.6 (12.84) 65.8 (12.72) 65.9 (12.03) 66.1 (12.50)
Screening % reversibility FEV1 28.2 (16.36) 26.2 (13.82) 30.0 (16.58) 28.1 (15.67)
Screening absolute FEV1 reversibility (ml) 577.1 (344.79) 533.7 (313.85) 650.6 (383.34) 587.2 (350.84)
Baseline pre-dose FEV1 (ml) 2264 (619.7) 2174 (587.7) 2250 (704.0) 2229 (637.9)
Baseline rescue-free 24-hour periods (%) 7.5 (19.49) 8.0 (19.48) 4.9 (16.21) NA
Baseline symptom-free periods (%) 5.1 (15.79) 6.0 (16.20) 2.4 (11.11) NA
Values are mean (SD) unless otherwise stated.
BD: twice-daily; FEV1: forced expiratory volume in one second; ITT: intent-to-treat; OD: once-daily; SAL: salmeterol; SD: standard deviation; VI: vilanterol.
Figure 1 CONSORT/patient flow diagram. *One patient was not randomised but received study treatment (placebo) in error. This patient was
not included in the ITT population. BD: twice-daily; ITT: intent-to-treat; OD: once-daily; SAL: salmeterol; VI: vilanterol.
Lötvall et al. Journal of Negative Results in BioMedicine 2014, 13:9 Page 3 of 9
http://www.jnrbm.com/content/13/1/9
Treatment with VI was well tolerated. More patients
reported on-treatment adverse events (AEs) in the VI
group (48%) than in the SAL (41%) or placebo (41%)
groups (Table 5); the incidence of on-treatment AEs
considered potentially treatment-related was low and
similar across groups (VI 2%, SAL 3%, placebo 4%). Two
serious AEs occurred: one fatal event in the placebo
group (sudden death) and one, non-fatal event in the VI
group (asthma exacerbation). Neither event was con-
sidered potentially treatment-related. No clinically sig-
nificant treatment-related changes in vital signs or
electrocardiogram (ECG) parameters were observed.
The most frequent on-treatment AEs are listed in
Table 5. Seven patients were withdrawn from the study
due to AEs other than severe asthma exacerbations (VI
2, SAL 2, placebo 3). Six patients had on-treatment se-
vere asthma exacerbations (VI 2, SAL 3, placebo 1); all
received systemic/oral corticosteroids and were with-
drawn from the study, with one patient in the VI arm
being hospitalised. Two further patients (VI 1, SAL 1)
reported severe asthma exacerbations during the post-
treatment period.
There were no clinically important treatment-related
changes in vital signs. A statistically, but not clinically,
significant increase relative to placebo in post-dose pulse
rate was seen at Week 12 with SAL (3.0 bpm; P = 0.013);
a numerical increase was also seen with VI (2.1 bpm, P =
0.072). There were no apparent treatment-related changes
in ECG parameters, and no clinically important liver
events were recorded.
Discussion
Current asthma treatment guidelines recommend the
addition of a LABA bronchodilator to ICS anti-
inflammatory therapy to provide sustained relief from
narrowing of the airways [2]. LABAs currently licensed for
the treatment of asthma include SAL and formoterol, and
are available with fluticasone propionate and budesonide,
respectively, in combination ICS/LABA formulations with
duration of action approximately 12 hours [14]. As such,
the currently available therapies require twice-daily dos-
ing. VI has previously been shown to display inherent 24-
hour activity [8]. In combination with the novel once-daily
ICS FF, VI will potentially offer patients with persistent
uncontrolled asthma a once-daily maintenance option,
simplifying treatment and potentially improving patient
adherence [15]. Despite the availability of effective man-
agement therapies, many patients continue to have sub-
optimal control [16], in part due to failure to adhere to
treatment regimens [17].
In the present study, no relative improvement in lung
function compared with placebo was seen with VI or
with the active comparator, SAL. Although the raw
changes from baseline for VI and SAL of 359 ml and
283 ml were similar to previous findings for the same
dose of VI (25 mcg) [8], the change observed with pla-
cebo (289 ml) was far higher than anticipated. The re-
markable magnitude of the placebo response meant that,
although substantial improvement from baseline in lung
function was observed with both active treatments, it is
not possible to draw meaningful conclusions about their
effects on lung function or asthma symptoms from this
study. Nevertheless, it is important that the findings of
this study are published in order to address potential
publication bias [18] and facilitate the use of the data in
meta-analyses.
The wisdom of including an active reference arm to
gauge assay sensitivity is clearly apparent. Previous stud-
ies performed by the sponsor have shown a clinical ef-
fect in adults and adolescents for SAL compared with
placebo on lung function, however, this study did not.
This supports the proposition that the reason for the
failure of VI to achieve a statistically significant improve-
ment relative to placebo is related to the unexpected
and sustained improvement in the placebo group, rather
than ineffectiveness of the active treatment. A possible
explanation for the placebo effect, that study batches
had been mis-labelled or cross-contaminated, was
Table 2 FEV1 change from baseline at week 12 (day 84),
ITT population
VI 25 mcg OD
(n = 101)
SAL 50 mcg BD
(n = 100)
Placebo
(n = 95)
LS mean change from
baseline (ml)
359 (41.6) 283 (41.9) 289 (42.9)
Difference vs.
placebo (ml)
70 −6
NA
95% CI (−48 – 188) (−124 – 113)
P-value 0.244 0.926
Values are weighted mean (SE) 0–24 hour FEV1 (ml) unless otherwise stated.
ANCOVA model with covariates of baseline FEV1, region, age, sex and treatment.
ANCOVA: analysis of covariates; BD: twice-daily; CI: confidence interval; FEV1:
forced expiratory volume in one second; ITT: intent-to-treat; LS: least squares;
n: number of patients used in analysis; NA: not applicable; OD: once-daily; SAL:
salmeterol; SE: standard error; VI: vilanterol.
Table 3 FEV1 change from baseline at week 12 (day 84)
by country, ITT population
VI 25 mcg OD
(n = 101)
SAL 50 mcg BD
(n = 100)
Placebo
(n = 95)
Germany (N = 28) 62 (127.6) 175 (156.2) 19 (221.6)
Peru (N = 104) 391 (433.8) 360 (364.7) 492 (591.9)
Poland (N = 59) 279 (310.4) 251 (513.9) 117 (615.6)
Ukraine (N = 43) 158 (238.7) 127 (198.5) 200 (253.9)
United States (N = 62) 519 (568.2) 392 (756.0) 400 (522.5)
Values are weighted mean (SD) 0–24 hour weighted mean serial FEV1 (ml).
BD: twice-daily; FEV1: forced expiratory volume in one second; ITT: intent-to-
treat; n: number of patients used in analysis; OD: once-daily; SAL: salmeterol;
SD: standard deviation; VI: vilanterol.
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investigated through the re-analysis of retention samples;
no evidence of incorrect treatment assignment or con-
tamination was found. Some variation was found in the
mean changes from baseline in the primary endpoint
across the five countries of the study. However, despite
the observed differences for improvements in lung func-
tion by country, the lack of evidence for a treatment-by-
region interaction for these improvements suggests that
the failure to achieve significance for the primary end-
point cannot be explained by inter-country variability.
Figure 2 Adjusted mean change from baseline (95% CI) in 24-hour post-dose FEV1 (l). At Week 12 (Day 84), ITT population. BD: twice-daily;
CI: confidence interval; FEV1: forced expiratory volume in one second; h: hour; ITT: intent-to-treat; LS: least squares; OD: once-daily; SAL: salmeterol;
VI: vilanterol.
Figure 3 Change from baseline in percentage of rescue-free 24-hour periods. Over Weeks 1–12, ITT population. BD: twice-daily; OD: once-daily;
SAL: salmeterol; SE: standard error; VI: vilanterol.
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One other possible explanation for the lack of efficacy
is that there could have been an increase in patient com-
pliance with background ICS during the study period. In
order to be eligible for the study, patients were required
to have been using ICS for at least 12 weeks prior to
screening, with a stable ICS dose for at least 4 weeks
prior to screening and during the run-in period. Patients
were excluded from randomisation if they were not
compliant with their ICS on at least 4 of the last 7 con-
secutive days of run-in. To confirm compliance, patients
in this study were asked daily via the e-diary if they had
used their ICS. However, real-world compliance with
ICS maintenance therapy among asthma patients is
Figure 4 Change from baseline in percentage of symptom-free 24-hour periods. Over Weeks 1–12, ITT population. BD: twice-daily; OD:
once-daily; SAL: salmeterol; SE: standard error; VI: vilanterol.
Table 4 Time to FEV1 increase of ≥12% and ≥200 ml from
baseline, ITT population
VI 25 mcg OD
(N = 115)
SAL 50 mcg BD
(N = 116)
Placebo
(N = 116)
Day 1
N 115 116 113
Number (%) patients
achieving threshold
increasea
65 (57) 59 (51) 36 (32)
Hazard ratio vs. placebo 2.358 1.750
NA
95% CI (1.542 – 3.606) (1.136 – 2.696)
Day 84
N 101 100 96
Number (%) patients
achieving threshold
increasea
57 (56) 54 (54) 51 (53)
Hazard ratio vs. placebo 0.993 0.911
NA
95% CI (0.659 – 1.495) (0.604 – 1.374)
a0–2 hours post-dose.
Cox proportional hazards model with covariates of baseline FEV1, sex, age,
region and treatment.
BD: twice-daily; CI: confidence interval; FEV1: forced expiratory volume in one
second; ITT: intent-to-treat; n: number of patients used in analysis; NA: not
applicable; OD: once-daily; SAL: salmeterol; VI: vilanterol.
Table 5 Occurrence of all adverse events (AEs) and most
frequent on-treatment AEs, ITT population
Number (%) of patients
VI 25 mcg OD
(N = 115)
SAL 50 mcg BD
(N = 116)
Placebo
(N = 116)
Any AE 55 (48) 48 (41) 47 (41)
Treatment-related AE 2 (2) 4 (3) 5 (4)
AE leading to withdrawal 2 (2) 2 (2) 3 (3)
Any serious AE 1 (<1) 0 (0) 1 (<1)
Any fatal AE 0 (0) 0 (0) 1 (<1)
Most frequent
adverse eventsa
Nasopharyngitis 9 (8) 7 (6) 12 (10)
Headache 10 (9) 9 (8) 5 (4)
Oropharyngeal pain 6 (5) 2 (2) 7 (6)
Upper respiratory
tract infection
2 (2) 2 (2) 8 (7)
a≥5% any treatment group.
BD: twice-daily; ITT: intent-to-treat; OD: once-daily; SAL: salmeterol; VI: vilanterol.
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often poor [19]. As such, it is conceivable that, despite
the eligibility criteria requiring stable ICS use, a propor-
tion of study participants may have only begun using
their ICS regularly immediately prior to baseline. Com-
paratively, in a previous study of VI versus placebo in
which compliance with ICS was required during the 4-
week run-in period, a statistically significant improve-
ment in lung function was seen [8].
Investigators were asked to counsel non-adherent pa-
tients on the importance of taking ICS at the prescribed
dose at each clinic visit. This may have resulted in an
improvement in adherence. The high degree of FEV1 re-
versibility observed among the population adds further
weight to the suggestion that ICS non-adherence may
have affected the outcome of this study. In future stud-
ies, confirmation of adherence during the run-in period
could be addressed by providing single-blind ICS with
dose counters, in order to better compare the ICS re-
sponse with the observed treatment effect following the
addition of vilanterol.
Conclusions
Substantial improvements in lung function and asthma
control were seen in all treatment groups, thus the un-
expectedly strong placebo response confounded inter-
pretation of the primary and secondary comparisons. As
such, no firm conclusions can be drawn from these data
regarding the efficacy of VI in asthma not controlled by
ICS alone; however, the safety data do confirm the toler-
ability of VI 25 mcg.
Materials and methods
This was a randomised, stratified, multicentre, double-
blind, double-dummy (i.e. all patients received both
devices, see below), parallel-group, placebo-controlled,
active-controlled Phase III study of 12 weeks’ duration
(GlaxoSmithKline study number: B2C112060; Clinical-
Trials.gov number: NCT01181895). It was conducted
between 15 September 2010 and 26 August 2011 at 34
centres in 5 countries (Germany, Peru, Poland, Ukraine
and USA). The study was approved by local ethics re-
view committees (see Additional file 4), and was con-
ducted in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines. All patients gave
written informed consent.
Eligibility criteria and interventions
In order to be eligible for screening, patients were aged
≥12 years, with a diagnosis of asthma for ≥12 weeks, and
use of ICS for ≥12 weeks with stable ICS dose (200–
1000 mcg fluticasone propionate or equivalent) for
≥4 weeks prior to screening. At screening, a best pre-
bronchodilator FEV1 of 40–90% of predicted normal and
demonstration of ≥12% and ≥200 ml reversibility of
FEV1 within 10–40 minutes of rescue medication were
required. To be eligible for randomisation, patients were
required to be symptomatic on their current ICS treat-
ment, defined as asthma symptom score ≥1 and/or res-
cue use on ≥4 of the last 7 days of the run-in, and
compliant with baseline medication on ≥4 of the last
7 days of the run-in period. Compliance was assessed by
a daily question of ICS compliance in the eDiary; pa-
tients were also contacted by telephone approximately
two weeks after Visit 1 to assess compliance. Patients
were excluded if they had a history of life-threatening
asthma, or asthma exacerbation requiring systemic
corticosteroids or emergency-room attendance within
3 months or overnight hospitalisation within 6 months
prior to Visit 1. All patients continued the same dose of
ICS throughout the treatment and follow-up periods. Pa-
tients were required to replace their current short-acting
beta2 agonists with albuterol/salbutamol inhaler pro-
vided at Visit 1 for use as needed during the study. All
systemic, oral, parenteral and depot corticosteroids were
prohibited from within 12 weeks of Visit 1. All anti-
leukotrienes, inhaled or oral LABA or ICS/LABA therap-
ies, theophyllines, anticholinergics, ketotifen, nedocromil
sodium and sodium cromoglycate were prohibited from
Visit 1 for the duration of the study. Any other medica-
tions with the potential to affect the course of asthma or
interact with sympathomimetic amines were prohibited
throughout the study.
Patients were stratified according to their screening
stable dose of ICS medication then randomised (1:1:1) to
receive VI 25 mcg via ELLIPTA™ dry powder inhaler
(representing an emitted dose from the dry powder in-
haler of 22 mcg) once daily, SAL 50 mcg via Diskus®/
Accuhaler® twice daily, or placebo over the duration of
the study (ELLIPTA™ is a trademark of the Glaxo-
SmithKline group of companies). Patients and investiga-
tors were blinded to treatment assignment. All patients
received double-blinded placebo dry powder inhaler and
Diskus® inhalers for use as appropriate (once daily and
twice daily, respectively). Inhalers containing active
treatment and placebo were indistinguishable. The ran-
domisation schedule was generated by RandAll (GlaxoS-
mithKline, UK) following stratification of the patients
according to dose of ICS medication (low, medium or
high). Patients were randomised to treatment using an
automated, telephone-based Registration and Medication
Ordering System (RAMOS). Treatment compliance was
measured by reviewing the dose counter on the inhalers.
The intent-to-treat (ITT) population comprised all pa-
tients randomised to treatment who received at least
one dose of study drug. The ITT population was used
for all efficacy and safety analyses other than those spe-
cified as being carried out in the per protocol (PP) popu-
lation. The PP population comprised all patients in the
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ITT population who did not have any full protocol devi-
ations. Patients with only partial deviations were consid-
ered part of the PP population, but their data were
excluded from the analysis from the date of the devi-
ation onwards. The decision to exclude a patient or
some of a patient’s data from the PP population was
made prior to breaking the blind.
Outcomes
The primary endpoint was change from baseline in 0–24
hours weighted mean FEV1 after 12 weeks. Mean change
from baseline in percentage rescue-free 24-hour periods
over the treatment period was a powered secondary end-
point. Other secondary endpoints were mean change
from baseline in the percentage of symptom-free 24-
hour periods and in individual 0–24 hours serial FEV1
assessments after 12 weeks. Other efficacy endpoints in-
cluded change from baseline in daily trough (pre-dose,
pre-rescue) PM PEF over 12 weeks of treatment, change
from baseline in daily AM PEF over 12 weeks of treat-
ment, time to increase in FEV1 to ≥12% and ≥200 ml
above baseline on Day 1 and Day 84 (0–2 hours), and
Global Assessment of Change questionnaire scores after
4 and 12 weeks of treatment. Safety endpoints included
the incidence of AEs (coded using the Medical Diction-
ary for Regulatory Activities dictionary), the incidence of
severe asthma exacerbations, vital signs (blood pressure,
pulse rate [measured at around 30 minutes post-dose, i.e.
around the time of maximal plasma concentration (Tmax)],
pre-dose ECG), haematology and clinical chemistry mea-
sures, measurement of serum cortisol, and routine liver
function assessments.
Statistical analysis
The study was powered for comparison of VI and SAL
with placebo; the study was not designed to assess differ-
ences between VI and SAL. Sample size was calculated
based on the primary endpoint and nominated powered
secondary endpoint. The sample size of 330 (110 pa-
tients per arm) was planned on the basis of an estimated
10% withdrawal rate to give 96% power to detect a
175 ml difference between VI 25 mcg and placebo in
weighted mean FEV1 at a two-sided significance level of
0.05 with anticipated standard deviation of 325 ml.
The following were all analysed using an analysis of
covariates model with effects due to baseline, region,
sex, age and treatment group: 0–24 hours weighted
mean serial FEV1 after 12 weeks, change from baseline
in percentage of rescue-free and symptom-free 24-hour
periods over the first 84 on-treatment days, individual
serial FEV1 assessment data at Week 12, and change
from baseline in AM and PM PEF for the 12-week treat-
ment period. For the primary and powered secondary
endpoints, treatment interaction-by-region was analysed.
Time to ≥12% and ≥200 ml increase above baseline
FEV1 was analysed using a Cox proportional hazards
model with treatment group as the explanatory variable
and baseline FEV1, region, sex and age as covariates,
with additional sensitivity analysis by log-rank test. Re-
sponses to global assessment of change questionnaire
after 4 and 12 weeks of treatment were assessed using
logistic (proportional odds) regression with covariates of
region, sex, age and treatment group to produce odds
ratios for estimated treatment differences.
In order to account for multiplicity across the key end-
points, a step-down testing hierarchy was applied. This
stipulated that statistical significance (P < 0.05) of the
primary endpoint treatment comparison of once-daily
VI 25 mcg to placebo was required in order for statis-
tical significance of powered secondary endpoints to be
inferred. If a statistically significant treatment difference in
both the primary and powered secondary endpoints was
found, testing would be performed on all remaining effi-
cacy endpoints without further multiplicity adjustment.
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